

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Empagliflozin for treating chronic heart failure with reduced ejection fraction

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

<p>The company submission noted people in lower socioeconomic groups and those with a black or South Asian family background may have a higher risk of developing heart failure and may do so at a younger age compared with people from white family backgrounds.</p>
--

<p>The committee also noted results of a meta-analysis by Zannad et al. (2020); suggested that SGLT2 inhibitors were most effective in people with a black or Asian family background. It noted that the empagliflozin trial mainly included people with a white family background. The committee noted that neither the empagliflozin or dapagliflozin trial was powered to show difference between subgroups of different ages or people from different family background.</p>
--

The clinical experts said that there is no reason to restrict empagliflozin use in adults based on age or ethnic background and the committee noted that its recommendation applied to all people regardless of family background.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee recognised that there were no ongoing clinical trials or data-collection to validate the possibility of differences in treatment effect because of family background. But, as a suggestion for future research, it considered there may be the potential to explore this issue further.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/a

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes. Equality issues have been described in section 3.10 of the FAD

Approved by Associate Director (name): Jasdeep Hayre

Date: 19/01/2022